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Abstract
The zinc finger antiviral protein (ZAP) is a host factor that mediates inhibition of viruses in the Filoviridae, Retroviridae and
Togaviridae families. We previously demonstrated that ZAP blocks replication of Sindbis virus (SINV), the prototype
Alphavirus in the Togaviridae family at an early step prior to translation of the incoming genome and that synergy between
ZAP and one or more interferon stimulated genes (ISGs) resulted in maximal inhibitory activity. The present study aimed to
identify those ISGs that synergize with ZAP to mediate Alphavirus inhibition. Using a library of lentiviruses individually
expressing more than 350 ISGs, we screened for inhibitory activity in interferon defective cells with or without ZAP
overexpression. Confirmatory tests of the 23 ISGs demonstrating the largest infection reduction in combination with ZAP
revealed that 16 were synergistic. Confirmatory tests of all potentially synergistic ISGs revealed 15 additional ISGs with a
statistically significant synergistic effect in combination with ZAP. These 31 ISGs are candidates for further mechanistic
studies. The number and diversity of the identified ZAP-synergistic ISGs lead us to speculate that ZAP may play an important
role in priming the cell for optimal ISG function.
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Introduction
Viruses in the Alphavirus genus (Togaviridae family) are arthropod-
borne viruses, which can infect a variety of birds and mammals
[1]. Humans, when inoculated through the bite of an infected
arthropod, support virus replication and can develop severe
disease including fever, debilitating arthritis, encephalitis, and
death. There are currently no licensed vaccines or specific
therapies available for prevention or treatment of diseases caused
by these important pathogens. The zinc finger antiviral protein
(ZAP, gene symbol ZC3HAV1), a host protein originally identified
in a screen as inhibitory to the retrovirus Moloney murine
leukemia virus [2], is able to inhibit the replication of multiple
Alphavirus genus members [3–6] when overexpressed in cultured
cells. ZAP also inhibits members of the Filoviridae family [7], but is
not able to inhibit all viruses [3]. ZAP mediates its antiviral activity
by binding to viral RNA [8,9], which for MMLV results in
exosome-mediated degradation of the viral RNA [10] in a cellular
process involving host helicases [11,12]. Using Sindbis virus
(SINV), the well-studied prototype alphavirus, we demonstrated
that ZAP blocks an early step after entry and prior to production
of the viral polyprotein [3] and that the inhibitory activity requires
ZAP self association [13]. ZAP is expressed via alternative splicing
as two distinct isoforms, with the longer of the two showing greater
anti-alphaviral activity [4].
The interferon (IFN) proteins are generated and secreted in
response to triggering of sensors within the cell that recognize
pathogen-associated molecular patterns (PAMPs), including viral
nucleic acid [14–16]. PAMPs bind to pattern recognition
receptors, consisting of cell surface or endosomally located Toll-
like receptors and cytosolic sensors. Upon binding, activation
results in a cascade of signaling events resulting in the phosphor-
ylation, activation, and nuclear translocation of the transcription
factors nuclear factor kappa-light-chain-enhancer of activated B
cells (NF-kB), interferon regulatory factor (IRF)-3 and in some cell
types, IRF-7. Transcriptional upregulation of the IFN-b gene by
IRF-3 and NF-kB results in IFN-b production, which, upon
secretion, binds to and signals through specific Type I IFN cell
surface receptors through both autocrine and paracrine mecha-
nisms. Phosphorylation, heterodimerization and nuclear translo-
cation of the latent signal transducers and activators of transcrip-
tion (STAT)1 and STAT2 transcription factors results in the
upregulation of hundreds of IFN-stimulated genes (ISGs), which
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genes, which also signal through the Type I IFN receptor, is
induced in cells expressing IRF-7, which itself is induced by Type I
IFN signaling, allowing for signal amplification at later stages
following infection or for early production of large amounts of
IFN-a in cell types that constitutively express IRF-7. The IFN-ls
[18,19] are another class of IFNs that mediate STAT1/STAT2-
dependent signaling after binding to the IFN-l receptor, resulting
in a similar upregulation of antiviral genes.
ZAP is induced by treatment of cells with interferon (IFN)-a/b
[5,20] or IFN-l [20], and its expression is also upregulated upon
viral infection [5,21]. Moreover, silencing of ZAP during IFN-a/b
treatment diminishes IFN’s ability to establish a cellular antiviral
state against SINV [6,22]. Interestingly, ZAP expression is also
directly induced by IRF-3 activation, and the short isoform
interacts with the intracellular pattern recognition receptor
retinoic acid-inducible gene-I (RIG-I) to enhance IFN-b produc-
tion. Thus ZAP is a key component of the host cell’s response to
viral infection potentially working at multiple levels to confer
resistance to alphavirus infection. Evidence suggests that ZAP
works in concert with other ISGs to confer maximal protection
against alphavirus infection. Previously, using gene silencing
approaches, it was shown in murine embryonic fibroblasts (MEFs)
that ZAP and ISG20 together provided greater control of SINV
replication than either ZAP or ISG20 alone [6]. In BHK-21
hamster fibroblasts, which are likely defective in IFN production
[23–27], we found that ZAP overexpression failed to block SINV
virion production, despite having a 10-fold effect on viral
polyprotein expression, and failed to prevent SINV-mediated cell
death [22]. Pretreatment with IFN-a, however, restored ZAP’s
antiviral and protective activity in a dose-dependent manner. In
that work, we demonstrated that expression of the amino terminal
domain of ZAP (NZAP) in BHK-21 cells failed to reduce viral
titers and pretreatment with IFN (100 U/ml) only reduced titers
by ,1 log. However, expression of NZAP and pretreatment with
IFN together resulted in a synergistic inhibition of virion
production, with an ,3 log reduction after high moi infection
(moi=5) and .4 log reduction upon low moi infection
(moi=0.01). Synergistic activity was also noted in MEFs, where
IFN treatment or NZAP expression each reduced virion produc-
tion by ,2 logs, while together a .4 log reduction was noted.
Thus one or more ISGs are able to work in concert with ZAP for
maximal virus inhibition.
In this study, we set out to identify which ISGs synergize with
ZAP to confer an antiviral state effective against infection with
SINV. Using a library of lentiviruses individually expressing 383
ISGs [28], we screened for ISG-mediated anti-SINV activity in
BHK-21 cells in the presence or absence of overexpressed rat
NZAP. Our results demonstrate that 69 of the tested ISGs
demonstrated a synergistic antiviral activity with ZAP. Follow-up
studies on the ISGs that blocked SINV in either cell type and/or
were potentially synergistic with ZAP in the initial screen verified
that 31 demonstrated a statistically significant synergy with ZAP.
The information will be utilized for future mechanistic studies
aimed at developing novel treatment or preventative strategies for
these important human pathogens in the Alphavirus genus.
Results
Differential ISG antiviral effect in BHK-21 cells with or
without ZAP overexpression
We utilized our previously described [22] IFN defective BHK-
21 cell derivatives expressing the Zeocin resistance gene (BHK/
HA-Zeo, control cells) or the active amino terminus of rat ZAP
fused to the zeocin resistance gene (BHK/NZAP-Zeo, ZAP cells)
to evaluate the efficacy of individual ISGs against SINV. Using
lentiviruses to individually express a library of ISGs [28], we tested
for inhibition of SINV replication in the absence (BHK/HA-Zeo)
or presence (BHK/NZAP-Zeo) of overexpressed NZAP. The
library was constructed such that a bicistronic message expressed
the ISG of interest followed by the red fluorescent protein TagRFP
under the control of an internal ribosome entry sequence (IRES).
For each ISG, one well of each cell type was transduced with the
appropriate VSV-G pseudotyped lentiviral particles, and 2 d later
the cells were challenged with SINV (TE/592J/GFP) expressing
enhanced green fluorescent protein (EGFP). We utilized a
lentivirus expressing Firefly luciferase (Fluc) as a negative control
not expected to affect SINV replication. After 8 h of infection, cells
were harvested and analyzed by flow cytometry to determine the
number of GFP positive (GFP+) cells within the transduced
(TagRFP+) population.
Of the 383 ISGs tested, 308 and 311 met our criteria for
analysis ($5,000 cells analyzed, $30% transduced) in the control,
and ZAP cells, respectively. In control cells expressing Fluc, 97.5%
of the cells were infected, while 89.1% of the ZAP cells expressing
Fluc were infected. Amongst all the ISGs, the mean infection
percentage in the control cells was 95.2 (SD=7.4). Expression of
11 ISGs resulted in infection levels of less than an arbitrary cutoff
of 85% (Fig. 1). ISGs that demonstrated the most potent SINV
inhibition in the control cells were IRF1, IL28RA, HPSE, RPL22,
MKX, MAFF, GBP2, RIG-I (also known as DDX58), IRF9,
CCL2, and PSMB9. These ISGs constitute anti-SINV ISGs that
can function independently of ZAP overexpression. In contrast, in
the ZAP cells, where the mean infection percentage was 88.1
(SD=13.5), expression of 80 ISGs, which constitutes more than
one quarter of those ISGs analyzed, resulted in infection levels of
less than 85% (Fig. 1). Thus expression of ZAP in concert with
other individual ISGs effectively promoted the antiviral state of
these cells. It should be noted that ISGs with antiviral activity in
control cells might not appear as antiviral in ZAP cells due to
infection rates being near the 85% cutoff (e.g. CCL2), or due to a
failure to meet our analysis criteria in ZAP cells (e.g. RPL22). The
percentage of infected cells for each ISG in the two cell types is
provided in Supplementary Table S1.
Comparison of ISG antiviral activity in control cells versus
ZAP-expressing cells and assessment for synergy
Of the 383 ISGs contained in the library, a total of 292 met our
criteria for analysis ($5,000 cells analyzed, $30% transduced) in
both control and ZAP cells. Fig. 2 shows the paired results for each
ISG in the two cell types, plotted in order by the percentage of
cells infected in the control cells. As noted above, expression of
ZAP without an ISG (Fluc control) resulted in a decrease from
97.5% infected to 89.1% infected (an 8.4% reduction, black and
red solid symbols, respectively). Compared to the inhibitory results
seen in the control cells, a large number of ISGs had an apparently
greater inhibitory effect in the ZAP-expressing cells, as can be seen
by the many data points (red open circles) falling well below the
corresponding result in the control cells.
To explore whether a given ISG and ZAP exhibited synergistic
antiviral activity, we utilized a Poisson regression model. The
observed rate of infection for a given ISG was calculated from the
four quadrant (RFP versus GFP) flow cytometric plots as the
number of double positive cells (Quadrant 2) divided by the total
number of RFP+ cells (Quadrants 1+2), and was assessed for a
statistically significant negative coefficient of the interaction term
of ZAP and ISG in the model (see Methods). A total of 69 ISGs
were found to exhibit statistically significant antiviral synergy in
ISGs Synergize with ZAP for Antiviral Activity
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list of the synergy testing results on the 292 ISGs is available in
Supplementary Table S1.
Confirmation of the synergistic hits
To confirm the synergistic activity of ISGs with ZAP against
SINV infection, we took two approaches to select genes for follow-
up screening. First, we focused on the difference in the percentage
of infected cells in the control cells compared to the ZAP cells (%
infected in control minus % infected in ZAP). Fig. 3 shows the
calculated differences, with the ISGs ranked according to the size
of the difference. Because our primary screen was performed with
just a single well for each ISG in the two cell types, we chose those
with the largest difference to confirm the potential synergistic
effect. Of the 292 ISGs interrogated in both cell types, the top 23,
all of which showed statistically significant synergy in the primary
screen (Table 1), were chosen for validation.
For each ISG chosen for confirmatory testing (IRF2, RIG-I,
IL28RA, C5orf39, PSMB9, IRF7, SSBP3, SAMD4A, CXCL9,
MDA5 (also known as IFIH1), MAB21L2, IFITM3, MYD88,
S100A8, IFIT5, UPP2, SMAD3, BTN3A3, COMMD3,
SAMHD1, RASSF4, FLJ39739, PHF11) we prepared newly
packaged VSV-G pseudotyped lentiviral particles, transduced the
control and ZAP cells, and 2 days later challenged the cells with
GFP-expressing SINV. As can be seen in Fig. 4, 98.3% of the
control cells expressing Fluc were infected, while 68.2% of the
ZAP cells expressing Fluc were infected. Thus ZAP expression
reduced the percentage of infected cells by 27.1 (compared to 8.4
in the primary screen). In the absence of ZAP (control cells, gray
bars) none of the tested ISGs reduced the percentage of infected
cells to levels below that seen upon ZAP expression (ZAP cells
expressing Fluc) with the exception of IL28RA, which reduced
infection to 18.1% of the cells. However, there were significant
reductions in the percentages of control cells infected upon
expression of 15 of the 23 ISGs including COMMD3, BTN3A3,
PSMB9, MYD88 (P,0.05), RASSF4, CXCL9, IRF7, SAMD4A,
IRF2 (P,0.01), SMAD3, IFITM3, SSBP3, C5orf39, RIG-I, and
IL28RA (P,0.001). Similar to our findings in the primary screen
(Figs. 2 and 3), for each of the ISGs tested, antiviral activity was
enhanced in the ZAP cells (Fig. 4, blue bars), suggesting synergistic
or additive activity against SINV between ZAP and the individual
ISGs. Of the 23 ISGs tested, significant reductions in the
percentages of ZAP cells infected were obtained upon expression
of 18 ISGs, which included UPP2, SMAD3, BTN3A3, RASSF4
(P,0.05), PHF11, IFIT5, CXCL9, IRF7, PSMB9, MDA5, SSBP3
(P,0.01), IFITM3, MYD88, C5orf39, SAMD4A, RIG-I, IRF2
and IL28RA (P,0.001). Amongst the tested ISGs, reduction in
the percentage of infected cells by ZAP co-expression (% infected
in the control cells minus % infected in the ZAP cells) ranged from
Figure 1. Anti-SINV activity of a library of 383 ISGs in control and ZAP-expressing cells. BHK/HA-Zeo (Control) cells or BHK/NZAP-Zeo cells
expressing the amino terminal domain of rat ZAP (ZAP cells) were transduced with lentiviruses co-expressing individual ISGs and the red fluorescent
protein TagRFP. After 2 d, the cells were challenged with SINV expressing GFP (moi=5). After 8 h, the cells were harvested and analyzed by flow
cytometry to determine the percentage of infected cells (GFP+) within the transduced (RFP+) population. Red symbols indicate cells expressing the
control protein, Fluc, while black open circles indicate cells expressing the individual ISGs. For each cell type, the line in the scatter plot indicates the
mean value for the percentage of infected cells. Gene symbols are shown for ISGs resulting in infection rates below an arbitrary cutoff of 85% (dashed
line).
doi:10.1371/journal.pone.0037398.g001
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45.4 (614.3). The values for the replicates of the confirmatory test
are available in Supplementary Table S2.
To ascertain whether the ISGs displayed synergistic activity
with ZAP against SINV, we utilized a two way ANOVA model to
estimate the ZAP6ISG interaction coefficient and corresponding
P value for each ISG (see Methods and Supplementary Table S2).
After adjustment of the P values for multiple comparisons
(Hommel’s adjustment) 16 of the 23 ISGs were found to exhibit
statistically significant antiviral synergy in combination with ZAP
(negative interaction coefficient and adjusted P,0.05, Table 2).
Thus IRF2, RIG-I, C5orf39, PSMB9, IRF7, SSBP3, SAMD4A,
CXCL9, MDA5, IFITM3, MYD88, IFIT5, UPP2, SMAD3,
BTN3A3, and PHF11 can each mediate a synergistic effect in
combination with ZAP to confer an anti-alphavirus state upon the
cell. Although a statistically significant synergistic effect was not
detected for ZAP and IL28RA, a potent antiviral state was
obtained upon coexpression that was greater than that seen for
either of the factors expressed individually.
In the second approach we took, we systematically tested all the
ISGs that reduced infection to less than 85% either in the control
(11 genes) or ZAP (80 genes) cells and/or synergized with ZAP to a
significant extent (Table 1; 69 genes with P,0.05), which resulted
in a list of 84 unique ISGs. In addition, we tested viperin, ISG15
and ISG20, which have been shown to inhibit SINV [6,29–32] but
were not present or were non-inhibitory in our initial screen. For
each ISG chosen, we prepared newly packaged VSV-G pseudo-
typed lentiviral particles, transduced triplicate wells of control and
ZAP cells, and infected them with GFP-expressing SINV in three
independent experiments. Data from each of the three screens are
shown in Supplementary Table S3. We noted some variability in
the percentage of infected cells in the three screens. Of the control
cells expressing Fluc, 84.4 to 95.7% were infected, while 55.2 to
94.7% of the ZAP cells expressing Fluc were infected. In the three
screens the reduction in the percentage of cells infected by ZAP
expression alone ranged from 24.6 to 29.2% (compared to 8.4 in
the primary screen and 27.1 in the confirmatory screen of the 23
ISGs). We utilized the same ANOVA model to identify synergistic
partners of ZAP with a significant P value of ,0.05 (see Methods
and Supplementary Table S3). In the three experiments, 11
(C5orf39, MDA5, IRF1, IRF2, IRF7, LAMP3, MYD88,
PRIC285, PSMB9, SAMD4A and SSBP3), 18 (C5orf39,
CCDC109B, RIG-I, DEFB1, GCH1, IFI44L, MDA5, IL28RA,
IRF1, IRF2, IRF7, ISG15, LMO2, MAP3K14, MKX, PCTK2,
PMAIP1 and VAMP5), and 11 (C5orf39, RIG-I, MDA5,
IL28RA, IRF1, IRF2, IRF7, MAP3K14, MYD88, PSMB9 and
SSBP3) ISGs demonstrated a greater effect against SINV in
combination with ZAP than ZAP or ISG expression alone
(Supplementary Table S3). Among the synergistic hits, 11 genes
(C5orf39, 4336 Via Linda Del Sur, Encinitas, CA 92024IL28RA,
Figure 2. Comparison of the antiviral activity of 292 ISGs in the control cells versus ZAP-expressing cells. For those 292 ISGs with
infection data in each cell type the results were sorted based on the percentage of infected cells in the control cells and the paired results are plotted
versus an arbitrary ISG number. For each ISG, black circles show the % infected in the control cells while red circles show the % infected in the ZAP
cells. Results obtained in the absence of ISG expression (Fluc) are shown with the filled circles.
doi:10.1371/journal.pone.0037398.g002
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and SSBP3) showed up in two or more of the replicate larger
confirmatory screens (Table 3). Of the genes identified as
synergistic in the confirmatory screen of the 23 ISGs nine
(C5orf39, IRF2, IRF7, MDA5, MYD88, PSMB9, RIG-I,
SAMD4A and SSBP3) were found to significantly up-regulate
the antiviral function of ZAP in at least one of the larger
confirmatory screens (Table 3).
To combine the data from the three larger confirmatory screens
of 87 ISGs, we normalized the data within each of the larger
screens and performed a statistical analysis for synergy on the
combined data, adjusting the P values for multiple comparisons
(Benjamini & Hochberg’s adjustment). Among the 87 ISGs tested
in three individual experiments, 21 (IRF2, C5orf39, RIG-I,
DDIT4, ISG15, IL28RA, MAP3K14, IRF7, BATF2,
CCDC109B, MDA5, UBE2L6, IRF1, CTCFL, C10orf10,
MYD88, CCDC75, GBP5, C4orf33, VAMP5, FAM70A) were
found to positively regulate ZAP activity against SINV (Supple-
mentary Table S3). Combining the results of the screen of 23 ISGs
with the combined analysis of the larger confirmatory screens
reveals that a total of 31 ISGs (BATF2, BTN3A3, C10orf10,
C4orf33, C5orf39, CCDC109B, CCDC75, CTCFL, CXCL9,
DDIT4, FAM70A, GBP5, IFIT5, IFITM3, IL28RA, IRF1, IRF2,
IRF7, ISG15, MAP3K14, MDA5, MYD88, PHF11, PSMB9,
RIG-I, SAMD4A, SMAD3, SSBP3, UBE2L6, UPP2, VAMP5)
demonstrated synergistic antiviral activity with ZAP.
Table 1. Significant estimated interaction coefficients from
Poisson regression of the primary screen results and the
corresponding P values.
Gene Symbol Interaction Coefficient P value Adjusted P value
1
IL28RA
2 22.4228 0 0
RIG-I 22.1559 0 0
IRF2 22.1088 0 0
IRF1 20.8664 0 0
PSMB9 20.733 0 0
C5orf39 20.6977 0 0
IRF7 20.6034 0 0
SSBP3 20.5504 0 0
SAMD4A 20.4467 0 0
CXCL9 20.4015 0 0
MDA5 20.3381 0 0
IFITM3 20.3163 0 0
MAB21L2 20.3131 0 0
MYD88 20.2517 0 0
HPSE 20.2507 0 0
COMMD3 20.2358 0 0
S100A8 20.2357 0 0
UPP2 20.2207 0 0
SMAD3 20.2169 0 0
GBP2 20.2151 0 0
MKX 20.2128 0 0
IFIT5 20.201 0 0
SAMHD1 20.1927 0 0
BTN3A3 20.1764 0 0
RASSF4 20.1761 0 0
SNN 20.1592 0 0
PHF11 20.1537 0 0
FLJ39739 20.1469 0 0
KIAA0040 20.1324 0 0
IFI44L 20.123 0 0
STAT3 20.1212 0 0
TAGAP 20.1212 0 0
LINCR 20.119 0 0
PCTK2 20.1172 0 0
GTPBP2 20.1147 0 0
FAM70A 20.1126 0 0
DEFB1 20.1118 0 0
EPSTI1 20.1116 0 0
LMO2 20.1108 0 0
GEM 20.1033 0 0
C4orf33 20.0992 0 0
GTPBP1 20.0979 0 0
DDIT4 20.0951 0 0
ANKRD22 20.0943 0 0
FBXO6 20.0939 0 0
MT1X 20.0925 0 0
PMAIP1 20.0906 1.00E204 1.00E204
ETV7 20.09 1.00E204 2.00E204
Table 1. Cont.
Gene Symbol Interaction Coefficient P value Adjusted P value
1
ABTB2 20.0885 1.00E204 3.00E204
SOCS2 20.085 1.00E204 1.00E204
ADFP 20.0818 3.00E204 6.00E204
UBE2L6 20.0762 3.00E204 6.00E204
LAMP3 20.0747 2.00E204 4.00E204
ARG2 20.0734 3.00E204 6.00E204
LRG1 20.07 3.00E204 6.00E204
VAMP5 20.066 0.0037 0.0058
CCDC109B 20.0657 0.0016 0.0028
CXCL10 20.0656 0.0023 0.0037
GCH1 20.0642 9.00E204 0.0016
GBP5 20.0629 0.0032 0.0052
PRIC285 20.0613 0.003 0.0049
ADAMDEC1 20.0583 0.0046 0.0071
PDK1 20.0582 0.0092 0.0135
CMAH 20.0531 0.0069 0.0102
ANGPTL1 20.0477 0.0232 0.0322
CCDC75 20.0455 0.0175 0.0247
ERLIN1 20.0451 0.0271 0.0374
DHX58 20.0449 0.0323 0.0436
BATF2 20.0448 0.0303 0.0415
1The P values were adjusted using the BH procedure to adjust for multiple
comparisons.
2ISGs listed in bold demonstrated the largest reduction in percentage of
infected cells upon coexpression of ZAP and were chosen for the initial follow
up confirmatory testing.
doi:10.1371/journal.pone.0037398.t001
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infection
Among the genes that synergized with ZAP, IRF2, RIG-I (also
known as DDX58) and IL28RA demonstrated the greatest
difference in infection level in the control compared to ZAP cells
and consistently showed up in the secondary screens, suggesting an
important role for these ISGs in modulating ZAP function. To
validate their synergistic interactions with ZAP, we transiently
knocked down IRF2, RIG-I and IL28RA with siRNA in the
presence or absence of ZAP silencing in Huh-7 cells, which were
then infected with SINV expressing a luciferase reporter.
Comparing untransfected cells to irrelevant siRNA-treated cells,
we found that siRNA transfection had no general effect on the
level of infection determined by luciferase assay (Fig. 5A). Silencing
of ZAP rescued SINV replication significantly (Fig. 5A) which was
shown previously in 293T cells [13]. Knockdown efficiency was
measured by qRT-PCR; ,80% silencing of the long isoform of
ZAP and ,30–70% silencing of the short isoform were achieved.
Silencing of RIG-I and IL28RA had no significant effect on
infection compared to irrelevant siRNA transfection, suggesting
that basal expression of these ISGs does not inhibit SINV (Fig. 5A).
IRF2 silencing enhanced viral replication although the effect was
not statistically significant in another similar experiment using a
higher moi (Fig. 5A, data not shown). ISG knockdown efficiency
was confirmed by qRT-PCR and ranged from 40 to 80% (Fig. 5B).
In addition, cell viability was similar among siRNA-transfected
cells, indicating that the difference in infection levels between
samples was not due to siRNA-induced cytotoxicity (data not
shown). When both ZAP and IRF2 were knocked down, viral
replication was significantly increased compared to ZAP or IRF2
silencing alone, which supports the results obtained in the ISG
overexpression screen and suggests that endogenous ZAP and
IRF2 might interact in a synergistic manner (Fig. 5).
Discussion
We previously determined that ZAP could synergize with one or
more factors induced upon treatment of cells with IFN-a to
mediate potent antiviral activity against the prototype Alphavirus,
SINV [22]. In the present study, we screened a lentiviral library
expressing over 350 individual ISGs [28] to identify those factors
capable of synergizing with ZAP to confer an antiviral state within
the cell. For the screen we chose BHK-21 cells, known to be
defective in the IFN pathway [23–27], to minimize any effects due
to IFN production within the cell culture system. We screened the
panel of ISGs for their antiviral activity against SINV in two
related BHK-21 derivatives, one transduced with the parental
retroviral vector expressing the zeocin resistance gene (control
cells) and one transduced with the retroviral vector expressing the
amino terminal zinc finger-containing domain of rat ZAP fused to
the zeocin resistance gene (NZAP-Zeo, ZAP cells).
Of the more than 300 ISGs with sufficient cell numbers and
transduction efficiency for analysis, a small number had clear
antiviral activity in the control cells in the absence of ZAP
Figure 3. Reduction in the percentage of infected cells by ZAP. For each ISG the reduction in the percentage of infected cells due to ZAP co-
expression was calculated by subtracting the percentage of infected cells in the ZAP cells from the percentage infected in the control cells. After
sorting, the differences were plotted versus an arbitrary ISG number. The difference seen between the control and ZAP cells in the absence of ISG
expression (Fluc) is shown by the red symbol. Gene symbols are shown for the 23 ISGs with the greatest difference in infection percentage ($18) due
to ZAP expression.
doi:10.1371/journal.pone.0037398.g003
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infection rate lower than an arbitrary cutoff of 85% (Fig. 1). Of all
the ISGs, IRF1 demonstrated the most robust inhibition (infection
percentage .11 SD below the mean in the control cells), and did
so independently of ZAP overexpression; in both cell types less
than 5% of the cells became infected. However, IRF1 did not
restrict SINV replication to similar levels in the absence of ZAP
overexpression in the confirmatory screens of 87 genes. In general,
the 87 ISG confirmatory screens had lower transduction
efficiencies, likely due to the use of a different transfection reagent
in order to prepare the lentiviral particles, and it is possible that
ISG expression levels are affected by the number of lentiviral
particles entering each cell. The IRF1 transcription factor was
previously found to exhibit antiviral activity against a number of
viruses, including the alphaviruses Venezuelan equine encephalitis
and chikungunya viruses [28,33]. A component of the IFN-l
receptor (IL28RA) was the next most potent antiviral ISG in the
control cells, resulting in an infection rate of less than 60% (.5S D
below the mean). This suggests that the IFN-ls may play an
important role in defense against alphaviruses, and their role in
preventing disease due to alphavirus infection deserves further
study.
In contrast to the results in the control, a large number of ISGs
exhibited antiviral activity in the ZAP cells, with 80 ISGs, more
than a quarter of those analyzed, meeting the arbitrary cutoff of
85% infected (Fig. 1). The ability of many ISGs to function more
effectively in the presence of ZAP (see also Fig. 2) suggests that in
addition to possible direct interactions with the individual ISGs to
mediate antiviral activity, ZAP may function to alter the
intracellular milieu in some manner, rendering it more permissive
for ISG function. It is of interest that ZAP expression is induced
directly upon IRF3 activation [34], prior to the ISG upregulation
that occurs in response to IFN-b. This early expression of ZAP
might alter the environment and prime the cell for more potent
ISG activity. In addition, it is also of interest that the short isoform
of ZAP was recently found to interact with the cytosolic PAMP
sensor, RIG-I (also known as DDX58) and to enhance IFN-b
production upon RIG-I engagement [35]. While ZAP may be
facilitating IFN production in these cells, which have an as yet
undefined defect(s) in IFN production, it is unlikely that any
increased IFN production is sufficient to induce a potent antiviral
state, since the expression of ZAP in the control cells resulted in
only a small to modest reduction in permissiveness to SINV
infection. Further studies are required to determine the direct and
global mechanisms by which ZAP is able to enhance ISG antiviral
function.
For the 292 genes with data for analysis in both the control and
ZAP cells we found that 69 ISGs showed statistically significant
synergy in combination with ZAP (Table 1). Interestingly, we
found no evidence for antiviral synergy with ISG20, which
previously was shown to have greater than additive antiviral
activity with ZAP [6]. Moreover, viperin did not demonstrate any
antiviral activity against SINV in our confirmatory screens,
whereas ISG15, although not antiviral by itself, demonstrated
synergistic antiviral activity with ZAP in one of our confirmatory
screens of the 87 genes. Possible explanations for these discrep-
ancies with previous reports [6,29–32] are the approaches utilized
(overexpression versus gene silencing) and the cell types used for
Figure 4. Confirmatory testing of the top ISG hits synergizing with ZAP. Triplicate wells of BHK/HA-Zeo cells (Control cells, gray bars) or
BHK/NZAP-Zeo cells expressing the amino terminal domain of rat ZAP (ZAP cells, blue bars) were transduced with lentiviruses co-expressing the
indicated ISGs and the red fluorescent protein TagRFP. After 2 d, the cells were challenged with SINV expressing GFP (moi=5). After 8 h, the cells
were harvested and analyzed by flow cytometry to determine the percentage of infected cells (GFP+) within the transduced (RFP+) population. Mean
values are plotted; error bars indicate the standard deviation. Dashed lines indicate the percentage of infection determined in control cells expressing
Fluc (gray) or ZAP cells expressing Fluc (blue). For FLJ39739 transduction of ZAP cells, there was only one replicate for analysis. Asterisks indicate
mean values statistically different than values obtained in Fluc-expressing cells for the corresponding cell type (unpaired t test, *,P ,0.05; **,P ,0.01;
***,P ,0.001).
doi:10.1371/journal.pone.0037398.g004
ISGs Synergize with ZAP for Antiviral Activity
PLoS ONE | www.plosone.org 7 May 2012 | Volume 7 | Issue 5 | e37398assessment of antiviral activity. Since we overexpressed the human
ISG library in a hamster cell line, some of the ISGs might not be
active or synergistic with ZAP due to the lack of compatible co-
factors. Human ISG15 might not function well with its conjugat-
ing enzyme UbE1L of the hamster species, which has been
demonstrated to play an important role in modulating ISG15
activity against SINV [30]. In addition, the overexpression system
allowed us to identify factors that blocked infection primarily at
early steps such as entry, translation and RNA replication. Due to
the high moi we used in the screens, almost all the cells were
infected in the first round and therefore could not be infected
again by newly synthesized virus, which could mask any effects on
virus production, release or spread. A previous study has shown
that viperin inhibited SINV production, which could explain why
it was not identified in our screens [29].
Since our primary screen was performed in singlicate wells, we
wanted to confirm the synergy for the top ranking ‘‘hits’’. We
ranked the ISGs based on the magnitude of the difference in the
percentage of infected cells expressing the ISG compared to the
percentage of infected cells expressing both ISG and ZAP (Fig. 3).
The top 23 were chosen for confirmatory testing (Fig. 4). Here,
using 2-way ANOVA analysis to assess for synergistic activity, we
found that 16 ISGs demonstrated a statistically significant
synergistic effect with ZAP against SINV (Table 2). Interestingly,
of the 23 ISGs chosen for validation, the majority were unable to
reduce the percentage of infected cells to lower than 85% in the
control cells, while all did so in the presence of ZAP. Given that we
chose the ISGs for follow up based on the magnitude of the
difference between cell types, this is not surprising. However, as
can be seen in Figs. 1 and 2, the majority of ISGs that
demonstrated anti-SINV activity in the ZAP cells were unable to
reduce infection percentages to below 85% in the control cells.
Whether this holds true in additional cell types will be important to
determine.
In order to identify additional ISG candidates that synergize
with ZAP, all the genes that exhibited inhibitory effects against
SINV in the presence or absence of ZAP, and those identified as
potentially synergistic in the primary screen were tested in a larger
screen of 87 genes in three independent experiments. Variability
was observed between the experiments, as the list of identified
synergistic ISGs was not completely agreeable between the
experiments. It is likely that the ISGs work in complex with other
factors, and as such their individual expression with ZAP might
not have dramatic effects on SINV replication. As a result, their
effects might be easily affected by variables such as transduction
efficiency of lentiviral particles, cell confluency and the ratio of
SINV particles to lentiviral integrations per cell. Although the
results were not identical between the experiments, there were 5, 8
and 8 genes in common for screens 1 and 2, screens 2 and 3, and
screens 1 and 3, respectively (Table 3). The overlap of identified
ISGs was statistically significant based on Fisher’s exact tests
(p=0.045, 3.17610
27 and 8.6610
25), which indicates that these
genes synergized with ZAP consistently and are important
candidates for mechanistic follow up.
To demonstrate ZAP-ISG synergy using an alternative
approach, we investigated the effects of double gene knockdown
on SINV. Among the three ISGs tested, IRF2 and ZAP
knockdown significantly enhanced viral replication compared to
ZAP silencing alone, suggesting that IRF2 might positively
regulate ZAP function. However, we did not observe a significant
increase in viral replication upon silencing RIG-I or IL28RA in
combination with ZAP, which might due to a number of factors.
First, the antiviral activity of endogenous ZAP was large,
potentially masking any additional effect caused by ISG silencing.
Similar results were observed in 293T and Huh-7.5 cells (data not
shown). Second, basal expression of ISGs might be low, limiting
their impact on SINV replication and therefore precluding
detection of synergy. Overexpression of the ISGs in an inducible
cell line might provide a better system for validation of ZAP-ISG
synergy as previously reported [6]. Alternatively, synergy could be
examined in the context of IFN treatment, where expression of the
ISGs would likely be increased compared to basal levels. However,
treatment with type I IFN would induce expression of many ISGs
followed by global changes in the antiviral state of the cells. As a
result, it could be difficult to study the effects of a specific ISG.
Finally, knockdown of RIG-I and IL28RA in Huh-7 cells was not
as efficient as knockdown of IRF2, which might explain why
silencing of the former ISGs did not affect SINV replication.
The mechanism by which ZAP might synergize with each of
these ISGs is uncertain and requires further experimentation. ZAP
and a synergistic ISG could target the same virus life cycle step or
could target different viral steps to result in synergistic inhibition.
Interestingly, some of the ISGs we identified as synergistic with
ZAP are known components or regulators of RNA sensing and
IFN induction pathways (IRF7, MYD88, MDA5, RIG-I, IRF2).
Thus in addition to its interaction with and enhancement of RIG-
I-mediated signaling and subsequent IFN-b production [35] one
might speculate that ZAP broadly targets components of the
innate immune PAMP recognition pathways to facilitate the
establishment of the cellular antiviral state. Alternatively, it is likely
Table 2. Estimated interaction coefficients from ANOVA of
the 23 selected ISGs and corresponding P values.
Gene Symbol Estimate (%) P value Adjusted P value
1
SAMD4A
2 245.5333 0 0
IRF2 244.0567 0 0
MDA5 236.7333 0 0
RIG-I 236.2433 0 0
SSBP3 232.2667 0 0
C5orf39 229.8 0 0
PSMB9 224.1333 0 0
MYD88 223.7333 0 0
PHF11 218.6333 0 1.00E204
IRF7 217.9667 0 2.00E204
IFIT5 217.5667 0 2.00E204
IFITM3 217.5333 0 2.00E204
CXCL9 216.4 1.00E204 7.00E204
BTN3A3 211.8333 0.0031 0.023
UPP2 211.2 0.0051 0.0355
SMAD3 211.0333 0.0057 0.0374
MAB21L2 210.1667 0.0107 0.0534
COMMD3 29.4667 0.0172 0.0688
RASSF4 29 0.0233 0.0932
SAMHD1 25.9333 0.1318 0.2707
S100A8 25.2667 0.1804 0.3609
FLJ3973 1.6 0.7386 0.7386
IL28RA 11.92 0.0029 0.023
1The P values were adjusted using Hommel’s adjustment for multiple
comparisons.
2Genes in bold font showed statistically significant synergy with ZAP (P,0.05).
doi:10.1371/journal.pone.0037398.t002
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through their ability to induce expression of other ISGs, which
then synergize with ZAP. It would be interesting to determine
whether de novo synthesis of transcripts is required for ISG-ZAP
interactions. Additional biochemical, cell biological, gene expres-
sion and signaling pathway analyses will be required to address
whether the ISG-ZAP synergistic activity is due to direct or
indirect interaction, and whether the synergistic ISGs and ZAP
target distinct SINV life cycle steps. Future studies addressing
whether these ISGs and ZAP can mediate synergistic antiviral
activity against other Alphavirus genus members will be crucial for
considering potential novel prevention or treatment strategies for
these important pathogens.
Table 3. Summary of ISGs that showed significant synergy with ZAP in the top-23 screen and the larger confirmatory screens.
Gene Symbol Top 23 Screen Larger Screen #1 Larger Screen #2 Larger Screen #3 Pooled Larger Screens
BATF2 NT
1 3
2
BTN3A3 3
C10orf10 NT 3
C4orf33 NT 3
C5orf39 33333
CCDC109B NT 33
CCDC75 NT 3
CTCFL NT 3
CXCL9 3
DDIT4 NT 3
DEFB1 NT 3
FAM70A NT 3
GBP5 NT 3
GCH1 NT 3
IFI44L NT 3
IFIT5 3
IFITM3 3
IL28RA 333
IRF1 NT 3333
IRF2 33333
IRF7 33333
ISG15 NT 33
LAMP3 NT 3
LMO2 NT 3
MAP3K14 NT 333
MDA5 33333
MKX NT 3
MYD88 33 33
PCTK2 NT 3
PHF11 3
PMAIP1 NT 3
PRIC285 NT 3
PSMB9 33 3
RIG-I 3 333
SAMD4A 33
SMAD3 3
SSBP3 33 3
UBE2L6 NT 3
UPP2 3
VAMP5 NT 33
1NT refers to a gene that was not tested in the particular screen.
2A tick mark represents a gene that significantly synergized with ZAP (P,0.05).
doi:10.1371/journal.pone.0037398.t003
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Cell lines
BHK-21 derivatives constitutively expressing the zeocin resis-
tance gene (BHK/HA-Zeo), or the amino terminal 254 amino
acids of the rat ZAP protein fused to the zeocin resistance gene
(BHK/NZAP-Zeo) were previously described [22] and were
maintained in minimal essential medium (MEM) containing
7.5% fetal bovine serum (FBS) and 200 mg/ml zeocin. The
BHK-21 cell line utilized for SINV titrations [3] and 293T cells
utilized for lentiviral pseudoparticle production [36] were main-
tained as previously described. The Huh-7 cell line utilized for
siRNA transfections were maintained in Dulbecco’s Modified
Eagle Medium (DMEM) containing 10% FBS and 16 non-
essential amino acids (NEAA).
Virus stocks and infections
SINV expressing EGFP from a duplicated viral subgenomic
promoter (SINV TE/592J-GFP) [37] and SINV expressing firefly
luciferase as a fusion with nsP3 (Toto1101/Luc) [3], were
generated by electroporation of BHK-21 cells with in vitro-
transcribed RNA and was titered on BHK-21 cells as previously
described [3]. The moi of infection was calculated based on BHK-
21-derived titers. Infections were conducted at 37uC for 1 h (with
intermittent rocking) in a minimum volume of Dulbecco’s
phosphate buffered saline (DPBS) containing 1% FBS. All work
with SINV was carried out under BSL2 conditions; incubation
with vesphene or bleach was utilized for virion inactivation.
The ISG library and preparation of VSV-G pseudotyped
lentiviral stocks
A library containing over 350 ISG cDNA clones inserted in a
lentiviral backbone was previously described [28]. Briefly, in this
TRIP-based [38] lentiviral expression library, the CMV promoter
drives expression of a transcript encoding the ISG, followed by an
IRES and sequences encoding the TagRFP protein. Lentiviral
particles pseudotyped with VSV-G were prepared by FuGENE- or
X-tremeGENE 9- (Roche) mediated cotransfection of 293T cells
with the pTRIP.CMV.IVSb.ISG.ires.TagRFP proviral plasmid,
HIV-1 gag-pol and VSV-G DNAs as described [28]. After 6 h, the
medium was replaced, and 48 h after the transfection, the medium
was harvested and adjusted to contain 4 mg/ml polybrene and
20 mM HEPES, pH 7. After clarification by centrifugation single
use aliquots were stored at 280uC. All lentivirus work was carried
out under BSL2 conditions; incubation with vesphene or bleach
was utilized for pseudoparticle inactivation.
Transduction of BHK/HA-Zeo and BHK/NZAP-Zeo cells
and SINV challenge
Cells were seeded in 24 well plates (5610
4 cells/well) one day
prior to transduction. On the day of transduction, the medium was
changed to one ml of MEM containing 3% FBS, 16nonessential
amino acids, 20 mM HEPES and 4 mg/ml polybrene. Pseudo-
particles (100 ml) were added to the wells and the cells were
transduced by spinoculation (1,500 g for 1 h, 37uC). After
overnight incubation, the medium was changed to MEM
Figure 5. Validation of synergy between ZAP and the top three ISGs in a knockdown system. A) Triplicate wells of Huh-7 cells were
transfected with irrelevant siRNA, ZAP-specific siRNA, ISG-specific siRNA that targets IRF2, RIG-I or IL28RA, or siRNAs that target both ZAP and an ISG.
ISG-specific siRNA was added to cells again on the second day after seeding. Forty-eight h after initial siRNA transfection, cells were infected with
Toto1101/Luc (moi=5). Viral replication was determined by firefly luciferase activity 4 h after infection. Huh-7 cells that were not transfected with
siRNA were included as a negative control. Means and standard deviations of triplicate samples are shown. Asterisks indicate mean values statistically
different between two siRNA treatments (unpaired t test, *, P,0.05; **, P,0.01; ***, P,0.001). B) Forty-eight h after initial siRNA transfection, total
RNA was extracted from the cells and used to generate cDNA. RNA levels of IRF2, RIG-I, IL28RA and RPS11 were measured by real-time PCR. The ISG
mRNA levels were normalized with that of RPS11, and the ISG mRNA levels in irrelevant siRNA-transfected cells were set as 1. Data are means +/2 SD
of one experiment in triplicate.
doi:10.1371/journal.pone.0037398.g005
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transduction, the cells were infected with SINV TE/592J-GFP
(moi=5), using an inoculum of 100 ml per well. For each cell type,
controls that were left untransduced, uninfected or both
untransduced and uninfected were included for the purposes of
setting the flow cytometry gates for RFP and GFP positivity. After
8 h of infection, the medium was removed and the cells were
washed with DPBS, harvested in Accumax Cell Aggregate
Dissociation Medium (eBioscience), and collected by centrifuga-
tion in 96-well format as described [28]. The cell pellets were
resuspended in 100 ml DBPS containing 1% FBS, to which an
equal volume of 4% paraformaldehyde in PBS was added. After
fixation at 4uC for at least 30 min, the cells were collected by
centrifugation and resuspended in 200 ml DPBS containing 3%
FBS for storage at 4uC in the dark until flow cytometric analysis.
Flow cytometry
A BD-LSRII equipped with 488 (GFP) and 561 (TagRFP) nm
lasers and a High Throughput sampler (BD Biosciences) was
utilized for flow cytometric data acquisition. Analysis was carried
out using FlowJo software (Treestar). After gating on live, singlet
cells based on forward and side scatter, a four quadrant plot was
generated using the untransduced, uninfected cells such that
$98% of the cells fell in quadrant 4 of the RFP vs. GFP plot (GFP
and RFP negative). Compensation, defined by untransduced,
uninfected (negative), untransduced, infected (GFP+ only), and
transduced, uninfected (RFP+ only), was applied to all the samples.
The compensated untransduced, uninfected sample was then
utilized to generate a four-quadrant plot as above and this was
applied to all samples. The cell counts from these quad plots were
utilized for the Poisson regression analysis of the primary screen
data (Table 1). To determine the percentage of cells that were
transduced (RFP+), and amongst those, the percentage infected
(GFP+), the live, singlet, compensated negative control sample was
viewed as histograms to set the GFP+ and RFP+ gates for all the
samples. The % infected for each sample, defined as the
percentage of GFP+ cells within the RFP+ population, was
obtained by applying the GFP+ gate to the RFP+ gate in all
samples. This value was utilized for Figs. 1–4 and for the ANOVA
regression analysis of the 23 ISGs with the greatest difference in %
infection between control and ZAP cells and the 87 synergistic
and/or antiviral ISGs that underwent confirmatory testing
(Table 2 and Supplementary Table S3).
Statistical analyses
For the purposes of our analysis we considered two variables
producing an effect greater than the sum of their individual effects
as exhibiting synergy. Both the primary screen data and the data
obtained in the confirmatory testing of the 23 and later 87 ISGs
were subjected to statistical analyses.
Poisson regression on the primary screen data. For the
primary screen data, the fact that our data set only consisted of a
single value for the percentage of infected cells for each ISG in the
control and ZAP cells precluded two-way ANOVA analysis.
However, count data were available from the 4 quadrant flow
cytometry data, where quadrant 2 (Q2) was RFP positive
(transduced, ISG-expressing) and GFP positive (infected) while
quadrant 1 (Q1) was RFP positive (transduced), but GFP negative
(uninfected). In our data, the rate was defined as the count of
RFP+ cells that were infected (GFP+), divided by the number of
cells exposed (total number of RFP+ cells). Using the quadrant
count data, Q2/(Q1+Q2) represents the rate of infection for each
sample, and Poisson regression was utilized, treating the number
of exposed cells as an offset, as shown in equation (1):
log E Q2i Xi~xi j ðÞ

Q1zQ2 ðÞ i

~b0zb1Zapizb2ISGizb3Zapi|ISGi
ð1Þ
In this equation, Q2i and (Q1+Q2)i were as described above.
E(Q2i|Xi=x i) represents the expected number of RFP+ cells that
were infected (GFP+) given the values of independent variables,
including intercept, main effects of ZAP, ISG and their
intersection term. If the coefficient (b3) of the interaction term of
ZAP and ISG is negative and significant, it implies that the relative
ratio of infection in the ZAP+ISG group is statistically significantly
less than the product of the relative ratios in the ZAP only group
and that in the ISG only group. The Benjamini–Hochberg
procedure was used to adjust P values for multiple comparisons.
Two-way ANOVA for the confirmatory testing. For the
confirmatory testing of the 23 ISGs with the greatest difference in
% infection between control and ZAP cells, in which there are
three replicates for each group, we utilized 2-way ANOVA to
model the percentage of transduced (RFP+) cells that were infected
(GFP+). The covariates include intercept, main effects of ZAP,
ISG and their intersection term. Those ISGs having a negative
estimated coefficient on the interaction term and a post-hoc
adjusted (Hommel’s adjustment) P value less than 0.05 were
considered to significantly synergize with ZAP.
For the confirmatory testing of the 87 synergistic and/or
antiviral ISGs identified by Poisson regression, in which there are
three replicates for each group and three screens (we conducted
the same experiment three times) for each gene, we utilized 2-way
ANOVA to model the percentage of transduced (RFP+) cells that
were infected (GFP+) separately for each screen. The covariates
include intercept, main effects of ZAP, ISG and their intersection
term. Those ISGs having a negative estimated coefficient on the
interaction term and a p-value less than 0.05 were considered to
potentially synergize with ZAP.
To combine these three screens (resulting in nine replicates for
each condition and greater statistical power), we firstly normalized
the percentage of transduced cells that were infected within each
screen (Z-score normalization). The values were further normal-
ized between screens such that the obtained scores would have a
mean of zero and a variance of 1 so that measures from different
screens on the same gene would be comparable. Finally, we
utilized 2-way ANOVA to model the resulting score. The
covariates include intercept, main effects of ZAP, ISG and their
intersection term. Those ISGs having a negative estimated
coefficient on the interaction term and an adjusted (Benjamini-
Hochberg adjustment) p-value less than 0.05 were considered to
significantly synergize with ZAP.
Software. All statistical analyses for synergy were carried out
using R language version 2.12 (www.r-project.org). Unpaired two-
tailed t-tests were performed in the PRISM software (GraphPad).
siRNA transfection
For small interfering RNA (siRNA) transfection, Huh-7 cells
were seeded the day before at 5610
4/well in a 24-well plate.
Triplicate samples were transfected using Lipofectamine RNAi-
MAX transfection reagent (Invitrogen) according to the manufac-
turer’s protocol, with either irrelevant siRNA, 6 pmol of ZAP
siRNA, 30 pmol of IRF2/RIG-I/IL28RA siRNA, or 6 pmol of
ZAP siRNA and 30 pmol of IRF2/RIG-I/IL28RA siRNA per
well. The total amount of siRNA used per well was kept constant
(36 pmol) by addition of irrelevant siRNA. One day post-
transfection, cells were again treated with 30 pmol of IRF2/
RIG-I/IL28RA siRNA to achieve efficient knockdown. siRNA
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SMARTpool siRNAs L-011705-00; Dharmacon), RIG-I specific
(ON-TARGETplus SMARTpool siRNAs L-012511-00; Dharma-
con), IL28RA specific (ON-TARGETplus SMARTpool siRNAs L-
007981-00; Dharmacon), or irrelevant (ON-TARGETplus Non-
targetting pool D-001810-10; Dharmacon). Forty-eight hours after
the first siRNA transfection, the cells were infected with Toto1101/
Luc (moi=5), using an inoculum of 100 ml per well. After 4 h of
infection, the medium was removed and the cells were lysed for
luciferase assay as previously reported [22]. Cell viability at the time
ofinfectionwasdeterminedusingtheCellTiter-Glo(Promega)assay
according to the manufacturer’s recommendations.
Quantitative Reverse-Transcription Polymerase Chain
Reaction (RT-PCR)
RNA was prepared using the RNeasy mini kit (Qiagen) and
quantified by absorption spectrophotometry using a NanoDrop.
RNA (1 mg) was used as a template for reverse transcription using
SuperScript III (Invitrogen) and random hexamers. Five mL of 10-
fold-diluted cDNA was used in a SYBR Green qPCR assay
(Roche) on the LightCycler 480 Real-Time PCR System (Roche).
The primers specific for RPS11, IRF2 and RIG-I were as
described [39], Primers for ZAP long and short isoforms were
from Qiagen (QuantiTect Primer Assay Hs_ZC3HAV1_1_SG
and Hs_ZC3HAV1_vb.1_SG), while IL28RA primers were
forward primer 59-AAGACCCTATTTCCAGTCACTCC-39
and reverse primer 59- GAACGTGTAGATGGTTCTGGC-39.
Expression was normalized to that of the housekeeping gene
RPS11 and to expression in cells treated with irrelevant siRNA.
Supporting Information
Table S1 Contains the data from the primary screen
and the Poisson regression analysis. The contents of each
Tab are as follows: Tab 1: For each cell type (Control or ZAP) the
percentage of the infected, ISG-expressing cells (%GFP-positive in
RFP-positive population) is shown for each ISG. Samples with less
than 5000 cells for analysis, or ,30% transduction efficiency are
excluded. A normalized value for each ISG within the cell type,
defined by the mean and standard deviation of all the samples, was
calculated in excel by the STANDARDIZE function. Tab 2: The
292 ISGs for which data were available in both the Control and ZAP
cells were sorted based on the percentage of infected cells in the
Control cells. The difference in the percentage infected (% infected in
the control cells minus % infected in the ZAP cells) is also displayed.
Tab 3: The data in Tab 2 is sorted by the magnitude of the
difference in percentage of cells infected in the two cell types. Tab 4:
For each ISG, the number of cells in quadrant 1 (RFP+,G F P 2)a n d
quadrant 2 (RFP+,G F P +) are shown for the two cell types. The
estimated interaction coefficient and corresponding P value (and
adjusted P value) obtained in the Poisson regression analysis are
shown for each ISG. Tab 5: The results from the Poisson regression
analysis (from Tab 4) on the 292 ISGs are displayed, sorted by the
magnitude of the estimated interaction coefficient.
(XLS)
Table S2 Contains the data from the confirmatory
testing of 23 ISGs and the ANOVA analysis. The contents
of each Tab are as follows: Tab 1: For each cell type (Control or
ZAP) the percentage of infected, ISG-expressing cells (%GFP-
positive in RFP-positive population) is shown for each of the 23
ISGs and Fluc control. The difference in the mean percentage
infected is also shown. Tab 2: The difference in the mean
percentage of cells infected in the two cell types (% infected in the
control cells minus % infected in the ZAP cells) is shown for the 23
ISGs and Fluc control, sorted by the magnitude of the difference.
Tab 3: The estimated interaction coefficients from ANOVA for
the 23 ISGs and the corresponding P values are shown.
(XLS)
Table S3 Contains the data from the confirmatory
testing of 87 ISGs and the ANOVA analysis. The contents
of each Tab are as follows: Tab 1: This tab shows the results from
the first of the three confirmatory screens of 87 ISGs. For each cell
type (Control or ZAP) the percentage of infected, ISG-expressing
cells (%GFP-positive in RFP-positive population) is shown. The
data displayed includes the average %infected from each replicate,
the standard deviation (SD), as well as the average transduction
percentage and standard deviation (SD). The average number of
cells analyzed after gating on singlet cells is also shown with the
standard deviation (SD). The results of the ANOVA analysis are
displayed at the bottom of the table. The estimate column refers to
the magnitudes of the synergy effects. Those ISGs having a
negative estimated coefficient on the interaction term and a P
value,0.05 were considered to potentially synergize with ZAP.
Tab 2: This tab shows the results from the second of the three
confirmatory screens of 87 ISGs. Tab 3: This tab shows the
results from the third of the three confirmatory screens of 87 ISGs.
The 87 genes were divided into two groups for performing the
transduction and infection steps of the screen. The genes
belonging to each group are highlighted by different colors. Tab
4: This tab displays the ANOVA results from the combined
normalized confirmatory screens of 87 ISGs. Those ISGs having a
negative estimated coefficient on the interaction term and an
adjusted P value,0.05 were considered to significantly synergize
with ZAP.
(XLS)
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